var data={"title":"Artesunate (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Artesunate (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/485090?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321348\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antimalarial Agent;</li>\n      <li>\n        Artemisinin Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321415\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria (severe), treatment:</b> IM, IV: 2.4 mg/kg/dose initially, followed by 2.4 mg/kg/dose at 12 hours, 24 hours, and 48 hours after the initial dose for a total of 4 doses over a period of 3 days; longer treatment duration (eg, an additional 4 days [Hess 2010]) may be required in severely-ill patients or in patients unable to transition to oral therapy (Hess 2010;  Rosenthal 2008). Transition to oral therapy at least 4 hours after the last dose of artesunate.  Appropriate oral therapies include atovaquone-proguanil, doxycycline (in patients &gt;8 years of age and nonpregnant adults), clindamycin, <b>or</b> mefloquine (CDC 2009; CDC 2014; Hess 2010; Rosenthal 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321414\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria (severe), treatment:</b> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;20 kg: 3 mg/kg/dose initially, followed by 3 mg/kg/dose at 12 hours, 24 hours, and 48 hours after the initial dose for a total of 4 doses over a period of 3 days (WHO 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents &ge;20 kg: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321416\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13332701\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary (Rosenthal 2008), use with caution (WHO 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13332702\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary (Rosenthal 2008), use with caution (WHO 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44942299\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: 110 mg [phosphate buffer solution provided as diluent]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321344\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;margin-left:0em;\">Investigational agent &ndash; not approved for use in the US</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Artesunate is available in the U.S. for IV use in patients with malaria through an Investigational New Drug (IND) protocol. To obtain artesunate via the IND protocol, clinicians must contact the Centers for Disease Control (CDC) Malaria Hotline at 770-488-7788 (business hours) or 770-488-7100 (nonbusiness hours) and request to speak with a CDC Malaria Branch clinician. Additional information from the CDC is available at <a target=\"_blank\" href=\"https://www.cdc.gov/laboratory/drugservice/formulary.html&amp;token=8fUMx+fB4trlY8x/Mo8Y9Ddj5kItZ1H7qlW/e3GJptY28xGubTU0DXWzUi5nl8+CwNhzfAcY95p7Mq5fGdd6Fg==&amp;TOPIC_ID=17088\" target=\"_blank\">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Eligibility criteria under the IND protocol include (Callender 2011; Hess 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- <b>Patients must have malaria:</b> Confirmation by microscopy or undetermined but strong clinical suspicion of <i>Plasmodium falciparum</i> or other <i>Plasmodium</i> spp. infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- <b>Patients must require parenteral therapy:</b> Unable to take oral medications, high-density parasitemia (eg, &gt;5%), or diagnosis of severe malaria (eg, seizures, shock, hemoglobin &lt;7 g/dL, disseminated intravascular coagulation, or acute respiratory distress syndrome [ARDS]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- <b>IV artesunate must be the preferred treatment:</b> IV artesunate is at least as readily available as IV quinidine or the patient has experienced quinidine failure (eg, parasitemia &gt;10% baseline after 48 hours of quinidine therapy), quinidine intolerance (eg, persistent hypotension, QRS prolongation &gt;50% of baseline or QTc interval prolongation &gt;25% of baseline), or contraindications to quinidine (eg, allergy, left bundle branch block, myasthenia gravis, digoxin toxicity).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For medical access to IV artesunate in Canada, please refer to special access information on the Public Health Agency of Canada website, http://www.phac-aspc.gc.ca/tmp-pmv/quinine/.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321427\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer via IV bolus slowly over 1 to 2 minutes through a 0.8-micron hydrophilic polyethersulfone filter (Hess 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer by IM injection into the anterior thigh (WHO 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25721878\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Malaria (severe), treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321359\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, ataxia, dizziness, headache, hyperreflexia, metallic taste, restlessness, slurred speech </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, pruritus, skin rash, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, diarrhea, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, hemolysis, neutropenia, reticulocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321352\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to artesunate or any component of the formulation (Hess, 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321353\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolysis: Postartemisinin delayed hemolysis (PADH), characterized by a decrease in hemoglobin due to hemolysis, may occur 1 to 3 weeks after artesunate administration; patients with high parasitemia may be at greater risk. Hemolysis is thought to be caused by delayed and synchronous clearance of once-infected erythrocytes (pitted cells), which continue to circulate after artesunate treatment. Hemoglobin levels usually decline in the second and third weeks after artesunate administration (Jaureguiberry 2014). Acute kidney injury may be associated with PADH (Plewes 2015). Monitor hemoglobin and renal function for 1 month after artesunate administration for the development of PADH (CDC [Paczkowsi 2014], Plewes 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe allergic reactions have been reported with oral administration of artesunate (Leonardi 2001); monitor for signs of hypersensitivity and discontinue treatment in patients who develop severe hypersensitivity reactions (eg, angioedema, dyspnea, erythema, anaphylaxis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: QT prolongation has been reported with other artemisinin derivatives (eg, artemether); however, one report suggests that the mean QTc interval was unaffected by artesunate (Maude 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407025\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407022\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=17088&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Inducers (Strong): May increase the metabolism of CYP2A6 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Inhibitors: May decrease serum concentrations of the active metabolite(s) of Artesunate. CYP2A6 Inhibitors may increase the serum concentration of Artesunate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: May decrease serum concentrations of the active metabolite(s) of Artesunate. Nevirapine may increase the serum concentration of Artesunate.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321350\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Studies in pregnant women have not revealed an increased risk of congenital abnormalities in newborns (Kovacs 2015, McGready 1998, McGready 2008). Malaria infection in pregnant women may be more severe than in nonpregnant women. Because <i>P. falciparum</i> malaria can cause maternal death, congenital malaria, and fetal loss, pregnant women traveling to malaria-endemic areas must use personal protection against mosquito bites. Artesunate is recommended for the treatment of severe malaria in pregnant women (Kovacs 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321351\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Low concentrations of the active metabolite of artesunate (dihydroartemisinin) can be detected in breast milk. Adverse events in the nursing infant would not be expected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321405\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Artesunate, a semisynthetic derivative of artemisinin, is a prodrug which is converted to dihydroartemisinin (DHA).  DHA is an antimalarial agent active against all of the erythrocytic stages of the parasite including gametocytes; inhibits parasite metabolism and enhances the clearance of infected erythrocytes.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Antiparasitic activity is hypothesized to involve cleavage of the Fe<sup>2+</sup>of  endoperoxide bridge, thereby producing free radicals and damaging parasite proteins. DHA may also inhibit calcium adenosine triphosphatase (cATP) of the sarcoplasmic endoplasmic reticulum and impair parasite protein folding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13321407\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Adults infected with severe malaria: Artesunate: 15.2 L/kg (range: 2.2 to 39 L/kg); Dihydroartemisinin (DHA): 1.9 L/kg (range: 0.8 to 11.5 L/kg) (Newton 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Dihydroartemisinin (DHA): 93% (WHO 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Artesunate (prodrug) is rapidly hydrolyzed by plasma esterases to an active metabolite, dihydroartemisinin (DHA). DHA undergoes hepatic metabolism via CYP2B6, CYP2C19, and CYP3A4 to inactive metabolites (Hess 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Artesunate: Adults infected with severe malaria: 0.22 hours (range: 0.08 to 0.61 hours); Dihydroartemisinin (DHA): 0.34 hours (range: 0.14 to 0.87 hours) (Newton 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Dihydroartemisinin (DHA): Adults infected with severe malaria: Within 15 minutes (Newton 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as DHA-glucuronide) (WHO 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13733211\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A-Keftal (IN);</li>\n      <li>Altinate (IN);</li>\n      <li>Arinate (BE);</li>\n      <li>Arinet (BD);</li>\n      <li>Artemax (ZW);</li>\n      <li>Artesun (KR);</li>\n      <li>Artesunet (BD);</li>\n      <li>Artex (BD);</li>\n      <li>Falciat (IN);</li>\n      <li>Falcigo (IN);</li>\n      <li>Junate (IN);</li>\n      <li>Lykavir (VN);</li>\n      <li>Plasmotrim (BR, TH);</li>\n      <li>Spy (IN);</li>\n      <li>Zesunate (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Artesun [prescribing information]. Guangxi China: Guilin Pharmaceutical Co, Ltd.; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barradell LB and Fitton A, &ldquo;Artesunate: A Review of Its Pharmacology and Theurapeutic Efficacy in the Treatment of Malaria,&rdquo; <i>Drugs</i>, 1995, 50(4):714-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/8536555/pubmed\" target=\"_blank\" id=\"8536555\">8536555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Callender DM and Hsue G, &ldquo;Artesunate: Investigational Drug for the Treatment of Severe Falciparum Malaria in Hawai'i,&rdquo; <i>Hawaii Medical J</i>, 2011, 70(4):77-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/21785506/pubmed\" target=\"_blank\" id=\"21785506\">21785506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. Artesunate is available to treat severe malaria in the United States. Available at:  <a href=\"http://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html\" target=\"_blank\">http://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html</a>. Accessed June 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. IND Protocol: Intravenous Artesunate for Treatment of Severe Malaria in the United States. #76,725. Revised May 6, 2014. <a href=\"http://www.cdc.gov/malaria/resources/pdf/artesunate/artesunate_protocol.pdf\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/artesunate/artesunate_protocol.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark RL, White TE, A Clode S, et al, &ldquo;Developmental Toxicity of Artesunate and an Artesunate Combination in the Rat and Rabbit,&rdquo; <i>Birth Defects Res B Dev Reprod Toxicol</i>, 2004, 71(6): 380-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/15617018/pubmed\" target=\"_blank\" id=\"15617018\">15617018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark RL, Brannen KC, Sanders JE, et al, &ldquo;Artesunate and Artelinic Acid: Association of Embryotoxicity, Reticulocytopenia, and Delayed Stimulation of Hematopoiesis in Pregnant Rats,&rdquo; <i>Birth Defects Res B Dev Reprod Toxicol</i>, 2011, 92(1) 2011, 92(1):52-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/21312322/pubmed\" target=\"_blank\" id=\"21312322\">21312322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis TM, Phuong HL, Ilett KF, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Severe Falciparum Malaria,&rdquo; <i>Antimicrob Agents Chemother</i>, 2001, 45(1):181-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/11120963/pubmed\" target=\"_blank\" id=\"11120963\">11120963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Clercq D, Vercruysse J, V&eacute;rle P, et al, &ldquo;Efficacy of artesunate against Schistosoma mansoni infections in Richard Toll, Senegal,&rdquo; <i>Trans R Soc Trop Med Hyg</i>, 2000, 94 (1):90&ndash;1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/10748910/pubmed\" target=\"_blank\" id=\"10748910\">10748910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dondorp A, Nosten F, Stepniewska K, et al, &ldquo;Artesunate versus Quinine for Treatment of Severe Falciparum Malaria: A Randomised Trial,&rdquo; <i>Lancet</i>, 2005, 366(9487):717-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/16125588/pubmed\" target=\"_blank\" id=\"16125588\">16125588</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Franco-Paredes C, Dismukes R, Nicolls D, et al, &ldquo;Neurotoxicity Due to Antimalarial Therapy Associated With Misdiagnosis of Malaria,&rdquo; <i>Clin Infect Dis</i>, 2005, 40(11):1710-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/15889385/pubmed\" target=\"_blank\" id=\"15889385\">15889385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gasasira AF, Kamya MR, Achan J, et al, &ldquo;High Risk of Neutropenia in HIV-infected Children Following Treatment With Artesunate Plus Amodiaquine for Uncomplicated Malaria in Uganda,&rdquo; <i>Clin Infect Dis</i>, 2008, 46(7), 985-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/18444813/pubmed\" target=\"_blank\" id=\"18444813\">18444813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hess KM, Goad JA, and Arguin PM, &ldquo;Intravenous Artesunate for the Treatment of Severe Malaria,&rdquo; <i>Ann Pharmacother</i>, 2010, 44(7-8):1250-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/20551300/pubmed\" target=\"_blank\" id=\"20551300\">20551300</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inyang-Etoh PC, Ejezie GC, Useh MF, et al, &ldquo;Efficacy of Artesunate in the Treatment of Urinary Schistosomiasis, in an Endemic Community in Nigeria,&rdquo; <i>Ann Trop Med Parasitol</i>, 2004, 98(5):491-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/15257799/pubmed\" target=\"_blank\" id=\"15257799\">15257799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaureguiberry S, Ndour PA, Roussel C, et al.  Postartensunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. <i>Blood</i>. 2014;124:167-175.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/24859359/pubmed\" target=\"_blank\" id=\"24859359\">24859359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kovacs SD, Rijken MJ, Stergachis A. Treating severe malaria in pregnancy: a review of the evidence. <i>Drug Saf</i>. 2015;38(2):165-181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/25556421/pubmed\" target=\"_blank\" id=\"25556421\">25556421</a>]</span><span class=\"doi\">10.1007/s40264-014-0261-9</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonardi E, Gilvary G, White NJ, et al, &ldquo;Severe Allergic Reactions to Oral Artesunate: A Report of Two Cases,&rdquo; <i>Trans R Soc Trop Med Hyg</i>, 2001, 95(22):182-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/11355556/pubmed\" target=\"_blank\" id=\"11355556\">11355556</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li Q, Cantilena LR, Leary KH, et al, &ldquo;Pharmacokinetic Profiles of Artesunate After Single Intravenous Doses at 0.5, 1, 2, 4, and 8 mg/kg in Healthy Volunteers: A Phase I Study,&rdquo; <i>Am J Trop Med Hyg</i>, 2009, 81(4):615-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/19815876/pubmed\" target=\"_blank\" id=\"19815876\">19815876</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li Q, Si Y, Smith KS, et al, &ldquo;Embryotoxicity of Artesunate in Animal Species Related to Drug Tissue Distribution and Toxicokinetic Profiles,&rdquo; <i>Birth Defects Res B Dev Reprod Toxicol</i>, 2008, 83(4):435-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/18636509/pubmed\" target=\"_blank\" id=\"18636509\">18636509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maude RJ, Plewes K, Faiz MA, et al. Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria? <i>Am J Trop Med Hyg</i>. 2009;80:126-132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/19141850/pubmed\" target=\"_blank\" id=\"19141850\">19141850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGready R, Cho T, Cho JJ, et al, &ldquo;Artemisinin Derivatives in the Treatment of Falciparum Malaria in Pregnancy,&rdquo; <i>Trans R Soc Trop Med Hyg</i>, 1998, 92(4):430&ndash;3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/9850401/pubmed\" target=\"_blank\" id=\"9850401\">9850401</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGready R, Cho T, Samuel, et al, &ldquo;Randomized Comparison of Quinine-Clindamycin versus Artesunate in the Treatment of Falciparum Malaria in Pregnancy,&rdquo; <i>Trans R Soc Trop Med Hyg</i>, 2001, 95(6):651-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/11816439/pubmed\" target=\"_blank\" id=\"11816439\">11816439</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGready R, Tan SO, Ashley EA, et al, &ldquo;A Randomised Controlled Trial of Artemether-Lumefantrine versus Artesunate for Uncomplicated Plasmodium Falciparum Treatment  in Pregnancy,&rdquo; <i>PLoS Med</i>, 2008, 5(12):e253<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/19265453/pubmed\" target=\"_blank\" id=\"19265453\">19265453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller LG and Panosian CB, &ldquo;Ataxia and Slurred Speech After Artesunate Treatment for Falciparum Malaria,&rdquo; <i>N Engl J Med</i>, 1997, 336(18):1328.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/9132599/pubmed\" target=\"_blank\" id=\"9132599\">9132599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newton PN, Barnes KI, Smith PJ, et al, &ldquo;The Pharmacokinetics of Intravenous Artesunate in Adults With Severe Falciparum Malaria,&rdquo; <i>Eur J Clin Pharmacol</i>, 2006, 62(12):1003-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/17089111/pubmed\" target=\"_blank\" id=\"17089111\">17089111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olliaro P, &ldquo;Disease and Drug Interactions: Treating Malaria With Artesunate Plus Amodiaquine in Patients Also Receiving Treatment for Concomitant HIV Infection,&rdquo; <i>Clin Infect Dis</i>, 2008, 46(7):992-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/18444814/pubmed\" target=\"_blank\" id=\"18444814\">18444814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Onyamboko MA, Meshnick SR, Fleckenstein L, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Artesunate and Dihydroartemisinin Following Oral Treatment in Pregnant women With Asymptomatic <i>Plasmodium falciparum</i> Infections in Kinshasa DRC,&rdquo; <i>Malar J</i>, 2011, 10:49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/21352601/pubmed\" target=\"_blank\" id=\"21352601\">21352601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paczkowski MM, Landman KL, Arguin PM. Update on Cases of Delayed Hemolysis After Parenteral Artesunate Therapy for Malaria- United States, 2008 and 2013. <i>MMWR Morb Mortal Wkly Rep</i>. 2014;63(34):753-755.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/25166926/pubmed\" target=\"_blank\" id=\"25166926\">25166926</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plewes K, Haider MS, Kingston HWF, et al. Severe falciparum malaria treated with artesunate complicated by delayed onset haemolysis and acute kidney injury. <i>Malar J</i>. 2015;14:246-253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/26081927/pubmed\" target=\"_blank\" id=\"26081927\">26081927</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenthal PJ, &ldquo;Artesunate for the Treatment of Severe Falciparum Malaria,&rdquo; <i>N Engl J Med</i>, 2008, 358(17):1829&ndash;36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/18434652/pubmed\" target=\"_blank\" id=\"18434652\">18434652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shapira MY, Resnick IB, Chou S, et al, &ldquo;Artesunate as a Potent Antiviral Agent in a Patient With Late Drug-Resistant Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation,&rdquo; <i>Clin Infect Dis</i>, 2008, 46(9):1455-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/18419454/pubmed\" target=\"_blank\" id=\"18419454\">18419454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      World Health Organization. Guidelines for the treatment of malaria, third edition. 2015. Available at http://www.who.int/malaria/publications/atoz/9789241549127/en/. Accessed June 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zoller T, Junghanss T, Kapaun A, et al, &ldquo;Intravenous Artesunate for Severe Malaria in Travelers, Europe,&rdquo; <i>Emerg Infect Dis</i>, 17(5):771-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/21529383/pubmed\" target=\"_blank\" id=\"21529383\">21529383</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 17088 Version 69.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13321348\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13321415\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F13321414\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F13321416\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13332701\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13332702\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F44942299\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F13321344\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13321427\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25721878\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13321359\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13321352\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13321353\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28407025\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28407022\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13321350\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13321351\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13321405\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F13321407\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F13733211\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/17088|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}